<DOC>
	<DOCNO>NCT00488891</DOCNO>
	<brief_summary>The purpose study examine long-term economic , functional clinical outcome schizophrenia patient require change antipsychotic treatment , change either paliperidone extend release ( ER ) another oral atypical antipsychotic agent ( AAP ) include aripiprazole , olanzapine , quetiapine , risperidone , ziprasidone .</brief_summary>
	<brief_title>The Paliperidone ER Observational Study Economic , Functional , Clinical Outcomes Patients With Schizophrenia</brief_title>
	<detailed_description>This 12-month , retrospective ( study look backward time , usually use medical record interview patient already know disease ) /prospective ( study patient identify follow forward time outcome study ) , open-label ( people involve know identity assign drug ) study clinical , functional economic outcome schizophrenia patient require change antipsychotic treatment . The patient randomly ( study drug assign chance like flip coin ) assign receive either paliperidone extend release ( ER ) one two prescriber-selected oral atypical antipsychotic ( AAPs ) . The AAPs include aripiprazole , olanzapine , quetiapine , risperidone , ziprasidone . Baseline define time patient begin take paliperidone ER AAP . The study `` pre/post '' design paliperidone ER patient serve control analysis healthcare utilization . If potential patient need switch current antipsychotic medication eligible study . The investigator determine patient may benefit equally switch either paliperidone ER ( extended release ) either 2 antipsychotic . Healthcare use 12-month period prior baseline ( `` pre-period '' ) compare 12-month period follow start paliperidone ER AAP ( `` post-period '' ) . Data period obtain study investigator enrol patient ' medical chart . Patients continue follow study , regardless change treatment , visit 5 month 12 withdrawn study . All patient receive medical care consistent local medical practice .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Must clinical diagnosis schizophrenia least 1 year prior screening Had receive treatment antipsychotic , judge candidate change antipsychotic basis either persistent symptom continue side effect Treating physician determine , patient enters study , start paliperidone extend release ( ER ) another least two possible atypical antipsychotic ( AAPs ) appropriate treatment patient Likely manage outpatient Must sign informed consent form DNA pharmacogenomic Have mental retardation , dementia , bipolar , schizoaffective disorder , schizophreniform disease , Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) psychiatric disorder deteriorate neurological illness determine clinical evaluation Established treatmentresistant schizophrenia , define treatment failure adequate trial two second generation atypicals , previous treatment clozapine , 4 hospitalization last 12 month History recent violence immediate risk suicide , harm self others , cause damage property , judgment investigator Patients unable swallow medication whole History circumstance may increase risk occurrence torsade de pointes and/or sudden death association use drug prolong QTc interval , include bradycardia , hypokalemia hypomagnesemia , concomitant use drug prolong QTc interval , presence congenital long QT syndrome Pregnant ( confirm urine pregnancy test perform baseline ) , plan become pregnant , breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperdone ER</keyword>
	<keyword>Invega</keyword>
	<keyword>Observational</keyword>
	<keyword>Antipsychotic agent</keyword>
</DOC>